[go: up one dir, main page]

NO976142D0 - Anvendelse av minst en NO syntase inhibitor i behandling av fölsom hud - Google Patents

Anvendelse av minst en NO syntase inhibitor i behandling av fölsom hud

Info

Publication number
NO976142D0
NO976142D0 NO976142A NO976142A NO976142D0 NO 976142 D0 NO976142 D0 NO 976142D0 NO 976142 A NO976142 A NO 976142A NO 976142 A NO976142 A NO 976142A NO 976142 D0 NO976142 D0 NO 976142D0
Authority
NO
Norway
Prior art keywords
sensitive skin
synthase inhibitor
treatment
symptoms associated
treat
Prior art date
Application number
NO976142A
Other languages
English (en)
Other versions
NO976142L (no
NO312272B1 (no
Inventor
Lionel Breton
Olivier De Lacharriere
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9483954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO976142(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of NO976142D0 publication Critical patent/NO976142D0/no
Publication of NO976142L publication Critical patent/NO976142L/no
Publication of NO312272B1 publication Critical patent/NO312272B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO19976142A 1995-10-26 1997-12-30 Anvendelse av minst en NO syntase inhibitor i behandling av fölsom hud NO312272B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512653A FR2740339B1 (fr) 1995-10-26 1995-10-26 Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
PCT/FR1996/001529 WO1997015280A1 (fr) 1995-10-26 1996-10-01 Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles

Publications (3)

Publication Number Publication Date
NO976142D0 true NO976142D0 (no) 1997-12-30
NO976142L NO976142L (no) 1998-06-03
NO312272B1 NO312272B1 (no) 2002-04-22

Family

ID=9483954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976142A NO312272B1 (no) 1995-10-26 1997-12-30 Anvendelse av minst en NO syntase inhibitor i behandling av fölsom hud

Country Status (9)

Country Link
US (1) US20020037854A1 (no)
EP (1) EP0859591B1 (no)
JP (1) JP3110050B2 (no)
AT (1) ATE247454T1 (no)
CA (1) CA2222303C (no)
DE (1) DE69629578D1 (no)
FR (1) FR2740339B1 (no)
NO (1) NO312272B1 (no)
WO (1) WO1997015280A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0969790A2 (de) * 1997-02-21 2000-01-12 Beiersdorf Aktiengesellschaft Zubereitungen für die behandlung von rosacea
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
FR2778562B1 (fr) * 1998-05-14 2000-08-04 Sephra Composition pharmaceutique, hygienique et/ou cosmetique contenant de l'eau de mer et de l'arginine
GR1003146B (el) * 1998-06-23 1999-06-02 Μεθοδος εξουδετερωσης των πολεμικων χημικων αεριων της μουσταρδας, της σαρινης και του δερματικου ερυθηματος απο την υπεριωδη ακτινοβολια του ηλιου με την χρησιμοποιηση αναστολεων των ελευθερων ριζων
DE19918750A1 (de) * 1999-04-24 2000-10-26 Beiersdorf Ag Wirkstoffe, kosmetische und dermatologische Zubereitungen für die Verbesserung der Barrierefunktion
DE19945484A1 (de) * 1999-09-22 2001-04-05 Kolb Bachofen Victoria NO-freisetzende topisch applizierbare Zusammensetzung
DE19962267A1 (de) * 1999-12-23 2001-06-28 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren NO-Synthasehemmern und einer oder mehreren Ascorbylverbindungen zur Stärkung der Barrierefunktion der Haut
DE10000840A1 (de) * 2000-01-12 2001-07-19 Beiersdorf Ag Verwendung eines oder mehrerer NO-Synthasehemmer
JP2001233764A (ja) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤
FR2808190B1 (fr) * 2000-04-28 2002-06-21 Oreal Extrait de vegetal de l'espece vitis vinifera comme inhibiteur de no-synthase et utilisations
FR2808189B1 (fr) 2000-04-28 2004-03-05 Oreal Lipochroman-6 comme inhibiteur de no-synthase et utilisations
FR2811567B1 (fr) * 2000-07-13 2003-01-17 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive de celle-ci, en association avec au moins un inhibiteur de no-synthase
DE10047204A1 (de) * 2000-09-23 2002-04-25 Henkel Kgaa Topische Hautbehandlungsmittel mit Arginase
FR2818136B1 (fr) * 2000-12-15 2004-10-15 Oreal Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un inhibiteur de no-synthase
DE10111052A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Steigerung der Ceramidbiosynthese
DE10111050A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthase des warmblütigenOrganismus ihre Wirkung entfaltet, zur Herstellung von kosmetischewn oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe unerwünschter Hautpigmentierung
DE10111049A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
DE10111054A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
FR2825923B1 (fr) * 2001-06-15 2006-04-07 Oreal Inhibiteur de no-synthase et utilisations
FR2825921B1 (fr) * 2001-06-15 2005-02-11 Oreal Inhibiteur de no-synthase et utilisations
FR2825920B1 (fr) * 2001-06-15 2006-04-28 Oreal Desferal comme inhibiteur de no-synthase et utilisations
FR2850578B1 (fr) * 2003-02-03 2006-07-28 Oreal Utilisation de n-arylmethylene ethylenediaminetriacetates, n-arylmethyleneiminodiacetates ou n,n'-diarylmethylene ethylenediamineacetates comme donneurs de no
CA2456035A1 (fr) * 2003-02-03 2004-08-03 L'oreal Utilisation de n-arylmethylene ethylenediaminetriacetates, n-arylmethyleneiminodiacetates ou n,n'-diarylmethylene ethylenediamineacetates comme donneurs de no
ES2421142T3 (es) * 2004-02-23 2013-08-29 Strategic Science & Technologies, Llc Administración tópica de un donante de óxido nítrico para mejorar el aspecto corporal y de la piel
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
AU2005235308B2 (en) * 2004-04-19 2011-12-01 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2006123676A1 (ja) * 2005-05-17 2006-11-23 Santen Pharmaceutical Co., Ltd. 角結膜障害の予防または治療剤
EP1749528A1 (en) * 2005-08-05 2007-02-07 Pharma C S.A. Pharmaceutical combinations containing a mu opioid agonist and an inhibitor of NO production
ES2370751T3 (es) * 2007-05-25 2011-12-22 Santen Pharmaceutical Co., Ltd Agente profiláctico o terapéutico para la degeneración macular asociada a la edad.
US20110009376A1 (en) * 2008-02-28 2011-01-13 Shin-Ichiro Hirai Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
ES2607476T3 (es) 2009-06-24 2017-03-31 Strategic Science & Technologies, Llc Composición tópica que contiene ibuprofeno
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
WO2017139457A1 (en) * 2016-02-11 2017-08-17 Ohio University Compositions and methods for inhibiting uvb -irradiation damage by targeting constitutive nitric oxide synthases (cnos)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0096521A3 (en) * 1982-06-01 1985-01-23 THE PROCTER & GAMBLE COMPANY Depilatory compositions
DE3620674A1 (de) * 1986-06-20 1987-12-23 Nattermann A & Cie Salbe zur behandlung von hauterkrankungen
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition
EP0729356A1 (en) * 1993-11-17 1996-09-04 Duke University Medical Center Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
ATE191470T1 (de) * 1994-06-15 2000-04-15 Wellcome Found Enzymhemmer

Also Published As

Publication number Publication date
NO976142L (no) 1998-06-03
JP3110050B2 (ja) 2000-11-20
CA2222303C (fr) 2003-01-14
NO312272B1 (no) 2002-04-22
FR2740339A1 (fr) 1997-04-30
FR2740339B1 (fr) 1997-12-05
EP0859591A1 (fr) 1998-08-26
ATE247454T1 (de) 2003-09-15
US20020037854A1 (en) 2002-03-28
WO1997015280A1 (fr) 1997-05-01
JPH10511404A (ja) 1998-11-04
EP0859591B1 (fr) 2003-08-20
CA2222303A1 (fr) 1997-05-01
DE69629578D1 (de) 2003-09-25

Similar Documents

Publication Publication Date Title
NO976142D0 (no) Anvendelse av minst en NO syntase inhibitor i behandling av fölsom hud
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
NO973900D0 (no) Nitrogenoksyd syntase inhibitorer
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
TR199901173T2 (xx) Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
ES2135674T3 (es) Composiciones cosmeticas antisolares y utilizaciones.
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
BR9507010A (pt) Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF
ES2125276T3 (es) Tratamiento de acne o de pseudofolliculitis barbae
DE69830069D1 (de) Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
DE69632632D1 (de) Behandlungsverfahren für darmadenome
DE69519582D1 (de) Kontrolle des haarwuchses
BR9917113A (pt) Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso
ATE239467T1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
BR0016415A (pt) Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
NO982582L (no) Fremgangsmaate for behandling av smerte
BR9612552A (pt) Processo para tratamento de autismo
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
SE9301606D0 (sv) Composition for the treatment of impaired hair growth
NO982854L (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
NO984190L (no) FremgangsmÕte for behandling av insomnia
ATE302605T1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis